Discontinued drugs in 2012: Cardiovascular drugs

Expert Opinion on Investigational Drugs

Volumn 22, Issue 11, 2013, Pages 1437-1451

  Zhao, Hong Ping ^a   Jiang, Hong Min ^a   Xiang, Bing Ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

ACT 280778; Apadenoson; Atopaxar; AZD 2927; BI 204; CXL 1020; CytoFab; Dyslipidemia therapy Veloxis pharmaceuticals; Eprotirome; GED aPC; Granotapide; Iferanserin ventrus; LCP AtorFen; MK 0524B; MP 136; NCX 226; NCX 6560; PF 3882845; REGN 728; RG 7236; RG 7273; Rusalatide acetate; Sitagliptin + atorvastatin; Tagatose spherix; TAK 591; TB 402; TC 5214; Tezosentan; Varespladib methyl; Varespladib sodium

Indexed keywords

A 001; ACT 280778; APADENOSON; ATOPAXAR; ATORVASTATIN; AZD 2927; AZILSARTAN; BI 204; BOSENTAN; CARDIOVASCULAR AGENT; CXL 1020; CYTOFAB; DEXMECAMYLAMINE; ENOXAPARIN; EPROTIROME; GRANOTAPIDE; LCP ATORFEN; LCP ATORFREN; LY 458202; MK 0524B; MP 136; NCX 1236; NCX 226; NCX 6560; PF 3882845; REGN 728; RG 7236; RG 7273; RIVAROXABAN; RUSALATIDE; SITAGLIPTIN; TAGATOSE SPHERIX; TAK 591; TB 402; TEZOSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB; VARESPLADIB METHYL; VELOXIS;

ACUTE CHEST SYNDROME; ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ANGINA PECTORIS; ANTHRAX; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC WOUND; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FUNDING; GLYCEMIC CONTROL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LUNG FIBROSIS; MALARIA; MEDICAL RESEARCH; MONEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PULMONARY HYPERTENSION; REPERFUSION INJURY; RESTENOSIS; SEPSIS; SEPTICEMIA; SINGLE DRUG DOSE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS; ULCER; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 84885747963     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.832198     Document Type: Article

References (77)

1. Cardiovascular disease. Available from: http://www.who.int/ cardiovascular- diseases/en/[Last accessed 17 May 2013]
2. Pammolli F, Magazzani L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10(6):428-38
3. Scannell JW, Blanckley A, Bolden H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11(3):191-200 .. In this paper, the decline in pharmaceutical R&D efficiency is diagnosed and four factors are considered to be primary causes of the inefficiency of new drugs R&D.
4. Arrowsmith J. A decade of change. Nat Rev Drug Discov 2012;11(1):17-18
5. Muller A. 2011 in reflection. Nat Rev Drug Discov 2012;11(1):6-8
6. Zhang XS, Xiang BR. Discontinued drugs in 2007: Cardiovascular drugs. Expert Opin Investig Drugs 2008;17(12):1817-28
7. Zhang XS, Xiang BR. Discontinued drugs in 2008: Cardiovascular drugs. Expert Opin Investig Drugs 2009;18(7):875-85
8. Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: Cardiovascular drugs. Expert Opin Investig Drugs 2011;20(10):1311-25
9. Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: Cardiovascular drugs. Expert Opin Investig Drugs 2012;21(10):1449-62 10. 2012 First Half Financial Results. Available from: http://www.nicox.com/uploads/default/files// HY20120727EN1. pdf [Last accessed 18 May 2013]
10. Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro- and announces changes to management. Available from: http://files. shareholder.com/downloads/ABEA- 4J4LWA/1879740064x0x571368/19fd6e2a-c671-49aa-bd75- 5bfddaa79103/ 230512%20Veloxis% 20Announces%20Restructuring%20of% 20Company.pdf [Last accessed 18 May 2013]
11. Development activities. Available from: http://www.takeda.com/company/ publications/pdf/index/pipeline-20121031-en.pdf [Last accessed 19 May 2013]
12. Company presentation, Roche, 12 Apr 2012. Available from: http://www.roche.com/irp1q12e-a.pdf [Last accessed 19 May 2013]
13. Roche Investor Presentation Q1 2011 Sales. Available from: http://www.roche.com/irp1q11e.pdf [Last accessed 19 May 2013]
14. Company presentation, Roche, 12 Apr 2012. Available from: http://www.roche.com/irp1q12e-a.pdf [Last accessed 19 May 2013]
15. Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01197391? term=REGN- 728&rank=1 [Last accessed 19 May 2013]
16. Form 10-Q, Regeneron, 24 Oct 2012. Available from: http://sec.gov/ Archives/edgar/data/872589/000153217612000004/regn-93012x10q. htm#sBD24B4DD64FB210E0CBD73 74D5F26B40 [Last accessed 19 May 2013]
17. Meyers MJ, Arhancet GB, Hockerman SL, et al. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3- cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo [g]indazole-7-carboxylic acid (PF- 3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J Med Chem 2010;53(16):5979-6002
18. Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845. Available from: http://clinicaltrials.gov/ct2/resultsterm=NCT00856258&Search=Search [Last accessed 19 May 2013]
19. Company pipeline, Pfizer, 8 Nov 2012. Available from: http://www.pfizer.com/files/research/pipeline/2012-1108/pipeline-2012-1108.pdf [Last accessed 19 May 2013]
20. Company pipeline, Mitsubishi, 8 May 2012. Available from: http://www.mtpharma. co.jp/e/develop/pipeline/e-pipeline1203.pdf [Last accessed 19 May 2013]
21. Company presentation, Cardiome, Apr 2012. Available from: http://cardiome.com/sites/default/files/financials/pdf/ FINAL%20MD%26A%20FY%202011. pdf [Last accessed 19 May 2013]
22. Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure. Available from: http://clinicaltrials.gov/ ct2/show/NCT01092325?term=CXL- 1020&rank=2 [Last accessed 20 May 2013]
23. A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure. Available from: http://clinicaltrials.gov/ct2/show/NCT01096043?term= CXL- 1020&rank=1 [Last accessed 21 May 2013]
24. IMPACTS Trial. Investigation of the Modulation of Phospholipase in Acute Chest Syndrome. Available from: http://clinicaltrials.gov/ct2/show/NCT00434473? term=ANSCD1121& rank=1 [Last accessed 21 May 2013]
25. A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects. Available from: http://ichgcp.net/clinical-trials-registry/NCT01522196 [Last accessed 29 July 2013]
26. Tezosentan in Patients With Pulmonary Arterial Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT01094067term=NCT01094067&rank=1 [Last accessed 21 May 2013]
27. Tezosentan in Pulmonary Arterial Hypertension. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01077297term=NCT01077297&rank= 1 [Last accessed 22 May 2013]
28. Phase III clinical trial of veletri for the treatment of acute heart failure symptoms does not meet primary efficacy objective. Available from: http://www1.actelion.com/en/investors/media-releases/index.page?newsId=1211970 [Last accessed 22 May 2013]
29. Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT00793234term=NCT00793234&rank=1 [Last accessed 24 July 2013]
30. Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT01344954term=NCT01344954&rank=1 [Last accessed 24 July 2013]
31. Enrollment complete in ThromboGenics, BioInvent TB-402 Phase IIb trial on VTE. Available from: http://www.newsmedical. net/news/20111217/ Enrollmentcomplete- in-ThromboGenics-BioInvent- TB-402-Phase-IIb-trial-on-VTE. aspx [Last accessed 23 May 2013]
32. BioInvent, Thrombo Genics announce results from TB-402 Phase IIb trial on VTE. Available from: http://www.newsmedical.net/news/20120605/BioInvent- ThromboGenics-announce-results-from- TB-402-Phase-IIb-trial-on-VTE.aspx [Last accessed 24 July 2013]
33. Form 10K, Spherix, 29 Mar 2012. Available from: http://www.sec.gov/ Archives/edgar/data/12239/000110465912022224/a12-1151-110k. htm [Last accessed 30 July 2013]
34. Spherix?s 2010 Annual Shareholder Meeting Script. Available from: http://www.spherix.com/documents/MeetingScript2010-000.pdf [Last accessed 23 May 2013]
35. Lu Y, Levin GV, Donner TW. Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 2008;10(2):109-34
36. Spherix Incorporated (Nasdaq: SPEX) January 2011. Available from: http://www.spherix.com/documents/SPEXCorporatePresentation1-11-FINAL. pdf [Last accessed 23 May 2013]
37. Japan Tobacco Inc. Clinical development (as of October 31, 2011). Available from: http://www.jt.com/investors/results/pharmaceuticals/pdf/P.L. 20111031-E.pdf [Last accessed 23 May 2013]
38. A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER). Available from: http://clinicaltrials.gov/ct2/ show/NCT01258907term=NCT01258907&rank=1 [Last accessed 24 July 2013]
39. Announcement of topline results from the GLACIER study. Available from: http://www.bioinvent.com/investors/press-releases/release.aspx? releaseid=682959 [Last accessed 23 May 2013]
40. BioInvent Reports Positive Phase I Results for BI-204, in development for prevention of cardiovascular conditions associated with atherosclerosis. Available from: http://www.bioinvent.com/mediacentre/press-releases/release. aspxreleaseid=424533
41. A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01396226?term=AZD- 2927&rank=2§=X3015#evnt [Last accessed 28 May 2013]
42. MeltDose- Technology Platform. Available from: http://www.veloxis.com/ technology.cfm [Last accessed 29 May 2013]
43. Pharmaceutical compositions comprising fenofibrate and atorvastatin. Available from: http://www.freshpatents.com/Pharmaceutical-compositions- comprisingfenofibrate- and-atorvastatindt20070118ptan20070014846. php [Last accessed 29 May 2013]
44. LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II Clinical Program. Available from: http://www.drugs.com/clinical-trials/ lifecyclepharma- announces-positive-data-lcpatorfen- phase-ii-clinical-program- 4190. html
45. Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro- and announces changes to management. Available from: http://files. shareholder.com/downloads/ABEA- 4J4LWA/1879740064x0x571368/19fd6e2a-c671-49aa-bd75- 5bfddaa79103/ 230512%20Veloxis% 20Announces%20Restructuring%20of% 20Company.pdf [Last accessed 30 July 2013]
46. Eisai heart drug looks safe in mid-stage trials. Available from: http://www.reuters.com/article/2010/08/30/heart-eisaiidUSLDE67T0IH20100830 [Last accessed 6 June 2013]
47. A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab-) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock. Available from: http://clinicaltrials.gov/ct2/show/ NCT01145560term=NCT01145560&rank=1 [Last accessed 24 July 2013]
48. BTG Announces Data from Phase IIb Study of AZD9773. Available from: http://www.btgplc.com/page/21061/media/press-releases/2012/btg-announcesdata- from-phase-iib-study-of-azd9773[Last accessed6June2013]
49. Essential Hypertension (REDUCE-1). Available from: http://clinicaltrials. gov/ct2/show/NCT01264692term=NCT01264692&rank=1 [Last accessed 24 July 2013]
50. Actelion announces first quarter 2012 financial results. Available from: http://www.actelion.com/en/investors/media-releases/index.page? newsId=1603781 [Last accessed 6 June 2013]
51. TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00899977term= NCT00899977&rank=1 [Last accessed 24 July 2013]
52. TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT00899977?term=TC- 5214&rank=7 [Last accessed 7 June 2013]
53. AstraZeneca updates on olaparib and TC-5214 development programmes. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/ 20111220-az-updates-olaparib-TC5214- development [Last accessed 30 July 2013]
54. Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued. Available from: http://www.astrazeneca. com/Media/Press-releases/Article/20032012tc5214-failed-phase-iiiendpoint [Last accessed 6 June 2013]
55. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A(2) (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial. Lancet 2009;373(9664):649-58
56. Anthera Halts VISTA-16 Clinical Study Due to Lack of Efficacy Following Recommendation by the Independent Data Safety Monitoring Board. Available from: http://cn.reuters.com/article/pressRelease/idUS238189+09-Mar-2012 +PRN20120309?symbol=ANTH.OQ [Last accessed 7 June 2013]
57. Form 10-Q, Merck, 9 Nov 2012. Available from: http://www.sec.gov/ Archives/edgar/data/310158/000119312512463586/d400394d10q. htm [Last accessed 14 June 2013]
58. Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect in Chronic Heart Disease. Available from: http://cn.reuters.com/article/pressRelease/idUS124947+03- Sep-2008+GNW20080903? sp=true [Last accessed 30 July 2013]
59. Carney DH, Olszewska-Pazdrak B. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother 2008;9(15):2717-26
60. Capstone Therapeutics Announces Operational Update. Available from: http://files.shareholder.com/downloads/OLGC/1650916856x0x535254/ 6a0b4efc-de04-405f-84f7-4810ead2d08d/CAPS-News-2012-1-20-General- Releases.pdf [Last accessed 14 June 2013]
61. Efficacy Study of Iferanserin to Treat Hemorrhoids. Available from: http://clinicaltrials.gov/ct2/show/NCT01483833term=NCT01483833&rank=1 [Last accessed 24 July 2013]
62. Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease. Available from: http://investor.ventrusbio.com/releasedetail.cfm?ReleaseID=639247 [Last accessed 27 July 2013]
63. S-1/A 1 v196825-s1a.htm. Available from: http://www.sec.gov/Archives/ edgar/data/1426800/000114420410052266/v196825-s1a.htm [Last accessed 13 June 2013]
64. Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids (VEN309). Available from: http://clinicaltrials.gov/ct2/show/ NCT01355874term=NCT01355874&rank=1 [Last accessed 24 July 2013]
65. Ventrus Biosciences Announces Results From Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease. Available from: http://investor.ventrusbio.com/releasedetail.cfm?ReleaseID=686060 [Last accessed 13 June 2013]
66. Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care (AKKA). Available from: http://clinicaltrials.gov/ct2/ show/NCT01410383term=NCT01410383&rank=1 [Last accessed 24 July 2013]
67. KARO BIO TERMINATES THE EPROTIROME PROGRAM. Available from: http://www.karobio.com/investormedia/pressreleaser/pressrelease? pid=639535 [Last accessed 13 June 2013]
68. Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT). Available from: http://clinicaltrials.gov/ct2/show/NCT00990327term=NCT00990327&rank=1 [Last accessed 24 July 2013]
69. Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI (ASPECT2). Available from: http://clinicaltrials.gov/ct2/show/NCT01313572term=NCT01313572&rank=1 [Last accessed 24 July 2013]
70. A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress. Available from: http://clinicaltrials.gov/ct2/show/NCT00380198term= NCT00380198&rank=1 [Last accessed 24 July 2013]
71. A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography. Available from: http://clinicaltrials.gov/ct2/ show/NCT00162084term=NCT00162084&rank=1 [Last accessed 24 July 2013]
72. Forest Laboratories 2012 Annual Report. Available from: http://investor.frx.com/sites/frx.investorhq.businesswire.com/files/report/file/ Full-Report.pdf [Last accessed 10 June 2013]
73. Branca MA. Academia given a helping hand in drug development. Nat Rev Drug Discov 2006;5:177
74. Scha?fer S, Kolkhof P. Failure is an option: Learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13:913-16 . This paper gives some insightful advice on how to reduce Phase II disappointments.
75. Czerepak EA, Ryser S. Drug approvals and failures: Implications for alliances. Nat Rev Drug Discov 2008;7:197-8
76. Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemp Clin Trials 2010;31:419-22
77. Padhy BM, Gupta YK. Drug repositioning: Re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011;57:153-60